WAT · Waters Corporation
AI read · Good for WAT
The AI's read
More drug experiments are increasing use of Waters’ lab tools and supplies. The company also said its China Biosciences business returned to growth, and its MOBILion purchase adds tools for studying proteins. The low end of the fourth-quarter profit range is below analysts’ estimate, but the range includes it and the sales range is above expectations. That caveat is smaller than the raised full-year targets and stronger demand.